CMAJ • August 12, 2008; 179 (4). doi:10.1503/cmaj.081032.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kondro, W.
PubMed
Right arrow Articles by Kondro, W.
Related Collections
Right arrow Canadian government
Right arrow Non-Canadian governments

NEWS

Briefly

Wayne Kondro

CMAJ

Class action approvals: The Quebec Superior Court has approved a $50 million suit against Pfizer Inc. related to its contraceptive Depo-Provera, which allegedly causes a decrease in bone density in women. Meanwhile, the Saskatchewan Court of Queen's Bench has expanded a suit against Merck Frosst Canada Ltd. to allow non-residents of the province (except Quebecers) to join their action against the drug rofecoxib (Vioxx). In November 2007, Merck & Co. agreed to a US$4.85 billion settlements for rofecoxib plaintiffs in the United States.

2,4-D safe: Health Canada's Pest Management Regulatory Agency says a scientific re-evaluation of the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) has concluded that it poses no risks to the health of children, adults, animals or the environment when used according to label instructions.

Antiretroviral access: About 3 million people had access to antiretroviral therapy in low-and middle-income countries in 2007, comprising roughly 31% of the 9.7 million who now need the life-saving HIV drugs, according to a new report (www.who.int) from the World Health Organization, UNAIDS and UNICEF. Although it took 2 years longer than once planned to achieve the "3 by 5" target, WHO Director-General Dr. Margaret Chan called it "a remarkable achievement for public health."

Discarded needles: The city of Ottawa will spend $100 000 over the course of the summer of 2008 to hire summer students, who'll roam streets and parks picking up discarded drug needles, which critics say are littering the streets of the national capital as a result of a program to distribute some 343 000 needles a year. City council also launched a $50 000 safe syringe study.


Figure 12
View larger version (127K):
[in this window]
[in a new window]

  		Photo by: Pete Birkinshaw

 



eLetters:

Read all eLetters

2,4-D a cancer risk
Gideon M. Forman
cmaj.ca, 15 Aug 2008 [Full text]
2,4-D safe?
Patricia E Van Boekel
cmaj.ca, 7 Oct 2008 [Full text]
This Article
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kondro, W.
PubMed
Right arrow Articles by Kondro, W.
Related Collections
Right arrow Canadian government
Right arrow Non-Canadian governments